Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

915 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.
Braess J, Amler S, Kreuzer KA, Spiekermann K, Lindemann HW, Lengfelder E, Graeven U, Staib P, Ludwig WD, Biersack H, Ko YD, Uppenkamp MJ, De Wit M, Korsten S, Peceny R, Gaska T, Schiel X, Behringer DM, Kiehl MG, Zinngrebe B, Meckenstock G, Roemer E, Medgenberg D, Spaeth-Schwalbe E, Massenkeil G, Hindahl H, Schwerdtfeger R, Trenn G, Sauerland C, Koch R, Lablans M, Faldum A, Görlich D, Bohlander SK, Schneider S, Dufour A, Buske C, Fiegl M, Subklewe M, Braess B, Unterhalt M, Baumgartner A, Wörmann B, Beelen D, Hiddemann W; AML-CG. Braess J, et al. Among authors: hiddemann w. Leukemia. 2018 Dec;32(12):2558-2571. doi: 10.1038/s41375-018-0268-9. Epub 2018 Oct 1. Leukemia. 2018. PMID: 30275528 Free PMC article. Clinical Trial.
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.
Braess J, Spiekermann K, Staib P, Grüneisen A, Wörmann B, Ludwig WD, Serve H, Reichle A, Peceny R, Oruzio D, Schmid C, Schiel X, Hentrich M, Sauerland C, Unterhalt M, Fiegl M, Kern W, Buske C, Bohlander S, Heinecke A, Baurmann H, Beelen DW, Berdel WE, Büchner T, Hiddemann W. Braess J, et al. Among authors: hiddemann w. Blood. 2009 Apr 23;113(17):3903-10. doi: 10.1182/blood-2008-07-162842. Epub 2009 Jan 8. Blood. 2009. PMID: 19131552 Free article. Clinical Trial.
Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.
Lengfelder E, Görlich D, Nowak D, Spiekermann K, Haferlach C, Krug U, Kreuzer KA, Braess J, Schliemann C, Lindemann HW, Horst HA, Schiel X, Flasshove M, Hecht A, Schnittger S, Schneider S, Wörmann B, Hofmann WK, Berdel WE, Bormann E, Sauerland C, Büchner T, Hiddemann W; German Acute Myeloid Leukemia Cooperative Group (AMLCG). Lengfelder E, et al. Among authors: hiddemann w. Eur J Haematol. 2018 Feb;100(2):154-162. doi: 10.1111/ejh.12994. Epub 2017 Dec 4. Eur J Haematol. 2018. PMID: 29114972 Clinical Trial.
A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia.
Herold T, Jurinovic V, Batcha AMN, Bamopoulos SA, Rothenberg-Thurley M, Ksienzyk B, Hartmann L, Greif PA, Phillippou-Massier J, Krebs S, Blum H, Amler S, Schneider S, Konstandin N, Sauerland MC, Görlich D, Berdel WE, Wörmann BJ, Tischer J, Subklewe M, Bohlander SK, Braess J, Hiddemann W, Metzeler KH, Mansmann U, Spiekermann K. Herold T, et al. Among authors: hiddemann w. Haematologica. 2018 Mar;103(3):456-465. doi: 10.3324/haematol.2017.178442. Epub 2017 Dec 14. Haematologica. 2018. PMID: 29242298 Free PMC article.
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
Rothenberg-Thurley M, Amler S, Goerlich D, Köhnke T, Konstandin NP, Schneider S, Sauerland MC, Herold T, Hubmann M, Ksienzyk B, Zellmeier E, Bohlander SK, Subklewe M, Faldum A, Hiddemann W, Braess J, Spiekermann K, Metzeler KH. Rothenberg-Thurley M, et al. Among authors: hiddemann w. Leukemia. 2018 Jul;32(7):1598-1608. doi: 10.1038/s41375-018-0034-z. Epub 2018 Feb 23. Leukemia. 2018. PMID: 29472724 Free PMC article.
The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.
Angenendt L, Bormann E, Pabst C, Alla V, Görlich D, Braun L, Dohlich K, Schwöppe C, Bohlander SK, Arteaga MF, Wethmar K, Hartmann W, Angenendt A, Kessler T, Mesters RM, Stelljes M, Rothenberg-Thurley M, Spiekermann K, Hébert J, Sauvageau G, Valk PJM, Löwenberg B, Serve H, Müller-Tidow C, Lenz G, Wörmann BJ, Sauerland MC, Hiddemann W, Berdel WE, Krug U, Metzeler KH, Mikesch JH, Herold T, Schliemann C. Angenendt L, et al. Among authors: hiddemann w. Leukemia. 2019 Dec;33(12):2830-2841. doi: 10.1038/s41375-019-0505-x. Epub 2019 Jun 10. Leukemia. 2019. PMID: 31182782
The clinical mutatome of core binding factor leukemia.
Opatz S, Bamopoulos SA, Metzeler KH, Herold T, Ksienzyk B, Bräundl K, Tschuri S, Vosberg S, Konstandin NP, Wang C, Hartmann L, Graf A, Krebs S, Blum H, Schneider S, Thiede C, Middeke JM, Stölzel F, Röllig C, Schetelig J, Ehninger G, Krämer A, Braess J, Görlich D, Sauerland MC, Berdel WE, Wörmann BJ, Hiddemann W, Spiekermann K, Bohlander SK, Greif PA. Opatz S, et al. Among authors: hiddemann w. Leukemia. 2020 Jun;34(6):1553-1562. doi: 10.1038/s41375-019-0697-0. Epub 2020 Jan 2. Leukemia. 2020. PMID: 31896782 Free PMC article.
915 results